Outcomes during delivery hospitalisations with inflammatory bowel disease

被引:2
|
作者
Yu, K. [1 ]
Faye, A. S. [2 ,3 ]
Wen, T. [4 ]
Guglielminotti, J. R. [5 ]
Huang, Y. [6 ]
Wright, J. D. [6 ]
D'Alton, M. E. [6 ]
Friedman, A. M. [6 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10032 USA
[2] Icahn Sch Med Mt Sinai, Dept Med, Dr Henry Janowitz Div Gastroenterol, New York, NY 10029 USA
[3] NYU, NYU Langone Hlth, Inflammatory Bowel Dis Ctr, Dept Med,Grossman Sch Med, New York, NY USA
[4] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA
[5] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA
[6] Columbia Univ, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
inflammatory bowel disease; maternal morbidity; maternal outcomes; PREGNANCY OUTCOMES; ULCERATIVE-COLITIS; WOMEN; PREVALENCE; FERTILITY; RISK; TRENDS; COHORT; IBD;
D O I
10.1111/1471-0528.17039
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To characterise inflammatory bowel disease (IBD) trends and associated risk during delivery hospitalisations. Design Cross-sectional. Setting US delivery hospitalisations. Population Delivery hospitalisations in the 2000-2018 National Inpatient Sample. Methods This study analysed a nationally representative hospital discharge database based on the presence of IBD. Temporal trends in IBD were analysed using joinpoint regression to estimate the average annual percent change (AAPC). IBD severity was characterised by the presence of diagnoses such as penetrating and stricturing disease and history of bowel resection. Risks for adverse outcomes were analysed based on presence of IBD. Poisson regression models were performed with unadjusted and adjusted risk ratios (aRR) as measures of effect. Main Outcome Measure Prevalence of IBD and associated adverse outcomes. Results Of 73 109 790 delivery hospitalisations, 89 965 had a diagnosis of IBD. IBD rose from 0.06% in 2000 to 0.21% in 2018 (AAPC 7.3%, 95% CI 6.7-7.9%). Among deliveries with IBD, IBD severity diagnoses increased from 4.1% to 8.1% from 2000 to 2018. In adjusted analysis, IBD was associated with increased risk for preterm delivery (aRR 1.50, 95% CI 1.47-1.53), severe maternal morbidity (aRR 1.93, 95% CI 1.83-2.04), venous thrombo-embolism (aRR 2.76, 95% CI 2.39-3.18) and surgical injury during caesarean delivery hospitalisation (aRR 5.03, 95% CI 4.76-5.31). In the presence of a severe IBD diagnosis, risk was further increased for all adverse outcomes. Conclusion IBD is increasing in the obstetric population and is associated with adverse outcomes. Risk is increased in the presence of a severe IBD diagnosis. Tweetable Abstract Deliveries among women with inflammatory bowel disease are increasing. Disease severity is associated with adverse outcomes.
引用
收藏
页码:1073 / 1083
页数:11
相关论文
共 50 条
  • [21] Outcomes of placebo therapy in inflammatory bowel disease
    Su, CY
    INFLAMMATORY BOWEL DISEASES, 2006, 12 (04) : 328 - 333
  • [22] Surgical Outcomes in the Elderly With Inflammatory Bowel Disease
    Bautista, Marita C.
    Otterson, Mary F.
    Zadvornova, Yelena
    Eastwood, Daniel
    Naik, Amar S.
    Stein, Daniel J.
    Venu, Nanda
    Perera, Lilani P.
    GASTROENTEROLOGY, 2012, 142 (05) : S665 - S666
  • [23] Obstetric outcomes of patients with inflammatory bowel disease
    Tondreau, Ambre
    Breuval, Coraline
    Gondry, Jean
    Fumery, Mathurin
    Foulon, Arthur
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2024, 310 (02) : 943 - 951
  • [24] Social Determinants of Outcomes in Inflammatory Bowel Disease
    Bernstein, Charles N.
    Walld, Randy
    Marrie, Ruth Ann
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (12): : 2036 - 2046
  • [25] Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
    Gara, Sirisha K.
    Guntipalli, Prathima
    Marzban, Sima
    Taqi, Muhammad
    Aryal, Vinayak
    Khan, Qurat ul ain
    Shah, Shahtaj A.
    Akbariromani, Hanieh
    Salinger, Darren
    Diaz-Miret, Miguel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [26] OUTCOMES OF ACUTE PANCREATITIS IN INFLAMMATORY BOWEL DISEASE
    Kroner, Paul T.
    Kesler, Alex M.
    Abader, Peter
    Afsh, Mohammad
    Brahmbhatt, Bhaumik
    Cangemi, John R.
    GASTROENTEROLOGY, 2019, 156 (06) : S865 - S865
  • [27] Colon delivery of resveratrol for the treatment of inflammatory bowel disease
    Sardou, Hossein Shahdadi
    Vosough, Paria Rahnama
    Abbaspour, Mohammadreza
    Akhgari, Abbas
    Kesharwani, Prashant
    Sahebkar, Amirhossein
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 92
  • [28] Drug delivery strategies in the therapy of inflammatory bowel disease
    Lautenschlaeger, Christian
    Schmidt, Carsten
    Fischer, Dagmar
    Stallmach, Andreas
    ADVANCED DRUG DELIVERY REVIEWS, 2014, 71 : 58 - 76
  • [29] Novel drug delivery systems for inflammatory bowel disease
    Yasmin, Farah
    Najeeb, Hala
    Shaikh, Shehryar
    Hasanain, Muhammad
    Naeem, Unaiza
    Moeed, Abdul
    Koritala, Thoyaja
    Hasan, Syedadeel
    Surani, Salim
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (18) : 1922 - 1933
  • [30] Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment
    Zhang, Wunan
    Michalowski, Cecilia Bohns
    Beloqui, Ana
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2021, 9